MVM has invested in high growth healthcare businesses since 1997. With teams in Boston and London, MVM has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare.

$

1

B

Assets managed

>

100


Collective years investing in healthcare

35


Exits

1997


Founded

Working with MVM

MVM partners with best-in-class management teams to bring innovative products to market, drive growth, make strategic acquisitions, and establish new standards of care in medicine.

We seek out portfolio companies that address significant unmet needs in large addressable markets. These include medical conditions for which there is no adequate treatment, therapies for which existing technologies are too expensive, or diseases for which there is no accurate diagnostic capability, among other situations.

In all of these cases, we prioritize businesses that have a clearly differentiated technology with durable protection against competition, whether through intellectual property, barriers to market entry, statutory exclusivity, or unique branding. After investment, we work closely with management teams to help the business achieve both its near and long term goals.

Work section image

Investment Approach

While MVM does not use fixed investment criteria, we focus on companies that fit the following profile.

Stage

We provide growth equity to commercial-stage businesses. In other words, our investments are intended to accelerate the growth and scale of companies that have commercially available products.

Sector

We invest broadly across healthcare and life sciences. We have made investments in medical devices, pharmaceuticals, diagnostics, digital health, health IT, life science tools, contract research, and contract manufacturing, among other areas. We focus on identifying differentiated products or technologies in each of these categories.

Size

We expect to make aggregate investments of $20 to 100 million in each of our portfolio companies over the life of our holding. In select circumstances, we have the capacity to make larger investments to support unique or creative financing opportunities.

Building image
Door image

Portfolio

MVM invests in innovative healthcare companies. Our active portfolio companies are transforming the delivery of healthcare by enabling higher quality, cost-effective care in large, global markets. We maintain a concentrated portfolio, focused on building world-class companies.

Exits

MVM has extensive experience guiding our portfolio companies to successful exits, including both acquisitions and initial public offerings. Selected former portfolio companies include:

City image

Latest news

MVM invests in Neurolens
September 12, 2022

Neurolens, a company commercializing innovative solutions to optimize vision, today announced completion of a $67 million financing. The financing was led by […]

MDxHealth acquires Oncotype DX GPS test
August 2, 2022

MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced it has entered into an […]

Nalu announces new CEO
July 14, 2022

Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today […]

MVM invests in Nalu Medical
February 17, 2022

CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]

Clarivate acquires Patient Connect
December 22, 2021

 Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]

MVM invests in Vero Biotech
December 15, 2021

VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the […]

MVM invests In Optinose
November 18, 2021

MVM invested $20 million in Optinose. Optinose markets XHANCE, an innovative drug delivery system that delivers steroids high and deep […]

Paragon 28, Inc. announces pricing of Initial Public Offering
October 15, 2021

ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ — Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and […]

MVM invests in InBrace
September 8, 2021

MVM invested $15 million in InBrace. InBrace is an orthodontic company that created the novel SmartwireTM, a new category in […]

Valneva announces positive Phase 3 pivotal results for its single-shot Chikungunya vaccine candidate
August 6, 2021

Saint Herblain (France), August 5, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the […]

Contact Us

info@mvm.com

MVM Partners

Old City Hall, 45 School Street

Boston MA 02108

MVM Partners

30 St George Street

London W1S 2FH